Atopic dermatitis biology implicates both IL-4 and IL-13, and whether blocking IL-13 alone would suffice was an open question. Adbry (tralokinumab) tested it commercially.
Tralokinumab specifically targets and neutralizes IL-13, preventing it from binding its receptors, in contrast to dupilumab’s blockade of the shared IL-4 receptor alpha subunit. The subcutaneous injection treats moderate-to-severe atopic dermatitis not adequately controlled with topical therapies.
Adbry has since expanded into adolescents and faces no biosimilar competition, but it competes against an entrenched market leader and newer oral JAK inhibitors. Its selectivity argument and conjunctivitis rate relative to dupilumab are the differentiators worth tracking.
